Gluten Exorphin B5 (GE-B5) is a food-derived opioid peptide, identified in vitro in enzymic digests of wheat gluten. It has been suggested that this peptide may play a regulatory role on pituitary secretion, since it stimulates prolactin (PRL) secretion when administered in the cerebral ventricles in rats. It is not known, however, if GE-B5 can exert this stimulatory action after peripheral administration. In order to clarify this aspect, we gave the following treatments to four groups of male rats: i.v. (i.v.) vehicle, GE-B5 3 mg/kg body wt. i.v., naloxone i.p. (i.p.) followed by vehicle i.v., naloxone i.p. followed by GE-B5 i.v. Blood samples for PRL were taken at intervals for 60 min after vehicle or GE-B5 administration. At the dose of 3 mg/kg body wt., GE-B5 induced a significant increase in PRL levels; naloxone completely abolished any effect of GE-B5 on PRL secretion. The present study indicates that GE-B5 stimulates PRL secretion after peripheral administration and that its action is mediated via classical opioid receptors; moreover, it identifies the min. peptide dose which must reach the blood in order to exert its action on PRL secretion.
Intravenous administration of the food-derived opioid peptide Gluten Exorphin B5 stimulates prolactin secretion in rats.
Fenude E;Alberico E;
2003
Abstract
Gluten Exorphin B5 (GE-B5) is a food-derived opioid peptide, identified in vitro in enzymic digests of wheat gluten. It has been suggested that this peptide may play a regulatory role on pituitary secretion, since it stimulates prolactin (PRL) secretion when administered in the cerebral ventricles in rats. It is not known, however, if GE-B5 can exert this stimulatory action after peripheral administration. In order to clarify this aspect, we gave the following treatments to four groups of male rats: i.v. (i.v.) vehicle, GE-B5 3 mg/kg body wt. i.v., naloxone i.p. (i.p.) followed by vehicle i.v., naloxone i.p. followed by GE-B5 i.v. Blood samples for PRL were taken at intervals for 60 min after vehicle or GE-B5 administration. At the dose of 3 mg/kg body wt., GE-B5 induced a significant increase in PRL levels; naloxone completely abolished any effect of GE-B5 on PRL secretion. The present study indicates that GE-B5 stimulates PRL secretion after peripheral administration and that its action is mediated via classical opioid receptors; moreover, it identifies the min. peptide dose which must reach the blood in order to exert its action on PRL secretion.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.